Sadly, in our world things usually go as you indicated, JA. In a more ideal world a manufacturer would be affraid that even in preclinical trials an impure substance may give him wrong info, which could be the beginning of a disastrous development. (On the other hand, many highly pure medications on the market are a disaster).